- Home
- VRCA vs ALXO Comparison
VRCA vs ALXO Comparison
Compare VRCA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 79.7M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ALXO |
|---|---|---|
| Price | $8.14 | $1.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | ★ 383.9K | 279.7K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $0.40 |
| 52 Week High | $10.50 | $2.27 |
Technical Indicators
Market Signals| Indicator | VRCA | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 67.02 | 50.89 |
| Support Level | $6.26 | $1.29 |
| Resistance Level | $9.78 | $1.56 |
| Average True Range (ATR) | 1.12 | 0.13 |
| MACD | 0.37 | 0.01 |
| Stochastic Oscillator | 75.22 | 51.09 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.